Trials / Conditions / Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis (RMS)

10 registered clinical trials studyying Relapsing Multiple Sclerosis (RMS) — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis NCT07006805	Cabaletta Bio	Phase 1 / Phase 2
Active Not Recruiting	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab NCT06869785	Novartis Pharmaceuticals	Phase 3
Recruiting	Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study NCT06486779	Novartis Pharmaceuticals	—
Terminated	A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofat NCT04878211	Novartis Pharmaceuticals	Phase 4
Completed	Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclero NCT04667949	Novartis Pharmaceuticals	Phase 4
Active Not Recruiting	An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis NCT04130997	TG Therapeutics, Inc.	Phase 3
Completed	Effects of Cladribine Tablets on the PK of Microgynon® NCT03745144	Merck KGaA, Darmstadt, Germany	Phase 1
Completed	Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclero NCT03277261	TG Therapeutics, Inc.	Phase 3
Completed	Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclero NCT03277248	TG Therapeutics, Inc.	Phase 3
Completed	Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS) NCT02921035	Merck KGaA, Darmstadt, Germany	—